Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 6 months to 10 years.~* mono-infection with P. falciparum detected by microscopy;~* parasitaemia of 250 - 200,000/μl asexual forms;~* presence of axillary temperature ≥37.5 °C or history of fever during the past 24 hours~* ability to swallow oral medication;~* ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and~* Informed consent from the parents or guardians of children.~Exclusion Criteria:~* mRDT negative~* presence of general danger signs in children aged 6 months to 10 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);~* weight under 5 Kg~* mixed or mono-infection with another Plasmodium species detected by microscopy;~* presence of severe malnutrition (defined as a child who has symmetrical oedema involving at least the feet or has a mid-upper arm circumference \< 110 mm in children ≤ 59 months; or BMI of \<16 in children aged 5 years and above)~* presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);~* regular medication, which may interfere with antimalarial pharmacokinetics;~* history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- single arm (Type: EXPERIMENTAL): Artesunate amodiaquine tablets containing 25/67.5 mg, 50/135mg and 100/270 mg base of artesunate-amodiaquine were administered according to body weight Dihrdroartemisinin piperaquine tablets containing 160/20mg and 320/40mg base of piperaquine dihydroartemisinin were administered according to body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).